Preclinical Pipeline Articles & Analysis
17 news found
A privately held company, PanTher is completing pre-clinical studies prior to initiating human trials and exploring opportunities for partnerships to expand its product pipeline. Suono Bio, a preclinical stage company, has developed breakthrough technology − the “SuonoCalmTM” system − designed to potentially enable ultra-rapid delivery of ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of ...
We are expecting to complete the CDMO divestiture in 2023, while we focus on advancing our lead preclinical program and our expanding pipeline and partnership opportunities.” Following a detailed review of its pipeline and growth opportunities, iBio will focus its resources on the continued development of its lead immuno-oncology assets ...
Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. ...
At the NK2022 conference, the Company presented preclinical data demonstrating that AFM28 exhibits greater cell surface retention on NK cells than conventional monoclonal antibodies. Furthermore, AFM28 induced lysis of CD123-positive tumor cells when pre-complexed or when co-administered with cryopreserved NK cells, suggesting that AFM28 in combination with NK cells maintains ...
Similar to the company’s recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. ...
The financing will be used to advance the Company’s preclinical pipeline of therapeutics and the Company’s discovery partnerships. ...
I share the team’s vision of industrializing drug discovery with technology, and I’m excited to accelerate the advancement of our wholly-owned small molecule pipeline through preclinical development and into the clinic.” Dr. ...
“These molecules represent the first targets under our collaboration with Lilly to address tissues outside the liver, highlighting the further expansion of our growing pipeline of RNAi therapeutics that address multiple tissues and cell types. With these nominations, we now have 18 core and collaborative pipeline programs in preclinical or ...
” Deep Genomics has validated the proficiency of its AI Workbench by advancing a lead cohort of ten programs into preclinical research and expects to nominate twenty more in the next three years. “By applying its innovative AI platform to create oligonucleotides as ‘programmable medicines,’ Deep Genomics has demonstrated remarkable productivity in ...
“This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline,” said Brendan Frey, PhD, FRSC, Founder & CEO of Deep Genomics. ...
At PsiOxus we are advancing our pipeline of clinical and preclinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring these tumor re-engineering products to patients. ...
CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law. ...
Longenesis - a digital health startup aiming towards the acceleration of the biomedical research pipeline worldwide, announced a release of its product Curator. It is a platform where clinical institutions and patient organizations are connected in consortiums with potential collaboration partners and study sponsors to initiate further cooperation. ...
Due to their natural generation in mice without negative thymic selection, these TCRs are of high specificity and high affinity. The Company has generated a pipeline of patented, unique TCR candidates for clinical development. Proceeds from the Series A round will be allocated to advancing at least four programs into the clinic, ramping-up preclinical work for ...
This financing will enable us to expand our AI technology in the pursuit of new therapeutic opportunities, to advance our Wilson program into the clinic, and to strategically partner assets emerging from our overflowing preclinical pipeline.” Deep Genomics uses AI to power every stage of drug development, from identifying therapeutic targets that were ...
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global ...